Sol-Gel Technologies (SLGL) Other Non-Current Assets (2015 - 2025)
Sol-Gel Technologies (SLGL) posted quarterly Other Non-Current Assets of $62000.0 for Q4 2025, down 94.73% year-over-year from $1.2 million in Q4 2024, and down 94.76% quarter-over-quarter from $1.2 million in Q2 2025.
Analysis
Sol-Gel Technologies (SLGL) Other Non-Current Assets (2015 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Other Non-Current Assets for 8 consecutive years, with $62000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 94.73% year-over-year to $62000.0; the TTM figure through Dec 2025 stood at $62000.0 (down 94.73% YoY), while the FY2025 annual figure was $62000.0, down 94.73% from the prior year.
- Other Non-Current Assets declined to $62000.0 in Q4 2025 per SLGL's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.0 million in Q1 2023 and bottomed at $45000.0 in Q1 2024.
- Historically, Other Non-Current Assets has averaged $1.3 million across 5 years, with a median of $1.2 million in 2021.
- On a YoY basis, Other Non-Current Assets climbed as much as 236.0% in 2024 and fell as far as 99.1% in 2024.
- Sol-Gel Technologies' Other Non-Current Assets stood at $1.2 million in 2021, then changed by 0.0% to $1.2 million in 2022, then tumbled by 69.57% to $350000.0 in 2023, then soared by 236.0% to $1.2 million in 2024, then sank by 94.73% to $62000.0 in 2025.
- Business Quant data shows SLGL's Other Non-Current Assets at $62000.0 in Q4 2025, $1.2 million in Q2 2025, and $1.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 62,000.00 |
| Jun 30, 2025 | 1.18 Mn |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 45,000.00 |
| Dec 31, 2023 | 350,000.00 |
| Jun 30, 2023 | 1.17 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Jun 30, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.15 Mn |
| Jun 30, 2021 | 1.15 Mn |
| Dec 31, 2020 | 1.15 Mn |
| Jun 30, 2020 | 1.15 Mn |
| Dec 31, 2019 | 350,000.00 |
| Jun 30, 2019 | 350,000.00 |
| Dec 31, 2018 | 350,000.00 |
| Jun 30, 2018 | 350,000.00 |
| Dec 31, 2016 | 9,000.00 |
| Dec 31, 2015 | 89,000.00 |